TCG Crossover

Venture capital firm

Recent changes

  1. Jun 25, 2026Invested in Ollin Biosciences (Series B, $330M) Crunchbase News

Portfolio

2 total

Recent Investment Activity

1
DateCompanyEventAmountValuationInvestorsSource
Jun 25, 2026Ollin BiosciencesSeries B$330M—
outlined = lead
Pulse story

Co-Investors

12

Latest Pulse

  1. Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.→
  2. Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease TherapiesOllin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.→

TCG Crossover FAQ

What companies has TCG Crossover invested in?

TCG Crossover's portfolio includes ADARx, Ollin Biosciences.

Who does TCG Crossover co-invest with most?

In the rounds Value Add tracks, TCG Crossover most often invests alongside AbbVie (1 shared deal), Bain Capital Life Sciences (1 shared deal), BlackRock (1 shared deal), OrbiMed Advisors (1 shared deal), SR One Capital Management (1 shared deal).

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction